文献速递心力衰竭与心肌病

达格列净联合螺内酯对比单药治疗射血分数保留心衰

Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

SOGALDI-PEF 为前瞻性随机开放盲终点交叉试验,纳入 108 例射血分数轻度降低或保留心衰患者,比较达格列净联合螺内酯与达格列净单药的疗效与安全性。联合治疗较单药降低 LogNT-proBNP 0.11(95%CI -0.22~-0.01,P=0.035),并增加 NT-proBNP 下降≥20% 的几率(OR 2.27,95%CI 1.16~4.44,P=0.016),但 eGFR 下降及血钾升高更明显。

要点

  • 联合螺内酯较单药进一步降低 NT-proBNP 0.11 Log 单位,NT-proBNP 下降≥20% 几率 OR 2.27。
  • 联合治疗 eGFR 下降 6.4 mL/min/1.73m2、血钾升高 0.32 mmol/L,高钾血症(>5.5 mmol/L)5 例 vs 1 例。
  • 联合治疗收缩压降低 5.2 mm Hg、尿白蛋白肌酐比降低 0.32 Log。

核心结论

  • 达格列净联合螺内酯较达格列净单药更显著降低 NT-proBNP,但肾功能下降及血钾升高更明显。

研究设计与样本

  • 前瞻性随机开放盲终点交叉试验,纳入 108 例射血分数轻度降低或保留心衰患者,每个治疗序列 12 周。

主要发现

  • 联合治疗较单药降低 LogNT-proBNP -0.11(95%CI -0.22~-0.01,P=0.035),对应 11% 相对降低。
  • 联合治疗增加 NT-proBNP 下降≥20% 的几率(OR 2.27,95%CI 1.16~4.44,P=0.016)。
  • 联合治疗收缩压降低 5.2 mm Hg(95%CI -8.4~-2.0),尿白蛋白肌酐比降低 0.32 Log(95%CI -0.54~-0.11)。
  • 联合治疗 eGFR 下降 6.4 mL/min/1.73m2(95%CI -8.3~-4.4),血钾升高 0.32 mmol/L(95%CI 0.23~0.41)。
  • 血钾>5.5 mmol/L 发生率联合组 5 例(4.8%)vs 单药组 1 例(0.9%)。

关键数值与推荐

  • 主要终点为达格列净/螺内酯联合与达格列净单药序列间 LogNT-proBNP 差异,检测 0.15 Log 差异所需样本量 108 例。

临床怎么用

  • 对射血分数轻度降低或保留心衰患者,可考虑达格列净联合螺内酯以进一步降低 NT-proBNP,但需监测肾功能和血钾。

局限性

  • 开放标签设计,样本量 108 例,交叉试验每个治疗序列 12 周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists improved heart failure outcomes in heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction; however, their combination was not tested in a randomized manner. Whether the SGLT2i/mineralocorticoid receptor antagonist combination offers benefits compared to SGLT2i alone requires dedicated trials. OBJECTIVES: This study aims to compare the efficacy and safety of dapagliflozin/spironolactone combination vs dapagliflozin alone in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. METHODS: This was a prospective randomized open, blinded endpoint crossover trial. A sample size of 108 patients was powered to detect 0.15 Log N-terminal pro-B-type natriuretic peptide (NT-proBNP) difference between the dapagliflozin/spironolactone combination and dapagliflozin alone sequences study primary outcome. Each treatment sequence was given for 12 weeks. RESULTS: One hundred eight patients were randomized. The median age was 76 years (Q1-Q3: 71-81 years), 57% were women, estimated glomerular filtration rate (eGFR) 72 mL/min/1.73 m2 (Q1-Q3: 49-89 mL/min/1.73 m2), potassium 4.3 mmol/L (Q1-Q3: 4.0-4.6 mmol/L), and 45% had diabetes. The median NT-proBNP was 746 pg/mL (Q1-Q3: 401-1,493 pg/mL) and median LogNT-proBNP 6.6 Log-units (Q1-Q3: 6.0-7.3 Log-units). Compared to dapagliflozin, dapagliflozin/spironolactone combination reduced LogNT-proBNP levels: -0.11 (95% CI: -0.22 to -0.01) Log-units (P = 0.035) corresponding to an 11% relative reduction and increased the odds of reaching ≥20% NT-proBNP reduction (OR: 2.27; 95% CI: 1.16-4.44; P = 0.016). Compared to dapagliflozin, dapagliflozin/spironolactone combination reduced systolic blood pressure (-5.2 mm Hg; 95% CI: -8.4 to -2.0 mm Hg), reduced Logurinary-albumin-to-creatinine ratio (-0.32 Log; 95% CI: -0.54 to -0.11 Log) decreased eGFR (-6.4 mL/min/1.73 m2; 95% CI: -8.3 to -4.4 mL/min/1.73 m2), and increased serum potassium (+0.32 mmol/L; 95% CI: 0.23-0.41 mmol/L) and the frequency of serum potassium (>5.5 mmol/L: 5 [4.8%] vs 1 [0.9%]). CONCLUSIONS: Dapagliflozin/spironolactone combination reduced NT-proBNP more than dapagliflozin. A greater eGFR decline and potassium increase was observed with dapagliflozin/spironolactone combination (SOGALDI-PEF [Dapagliflozin With or Without Spironolactone for HFpEF]; NCT05676684).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ferreira JP, Vasques-Nóvoa F, Saraiva F, et al. Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial. J Am Coll Cardiol. 2025. PMID: 40738559. doi:10.1016/j.jacc.2025.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。